Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Cytokines | Research

Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study

Authors: Hao Xiong, Huitao Zhang, Jun Bai, Yanhong Li, Lijuan Li, Liansheng Zhang

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Objective

In the pathogenesis of myeloproliferative neoplasms (MPN), inflammation plays an important role. However, it is unclear whether there is a causal link between inflammation and MPNs. We used a bidirectional, two-sample Mendelian randomization (MR) approach to investigate the causal relationship between systemic inflammatory cytokines and myeloproliferative neoplasms.

Methods

A genome-wide association study (GWAS) of 8293 European participants identified genetic instrumental variables for circulating cytokines and growth factors. Summary statistics of MPN were obtained from a GWAS including 1086 cases and 407,155 controls of European ancestry. The inverse-variance-weighted method was mainly used to compute odds ratios (OR) and 95% confidence intervals (Cl).

Results

Our results showed that higher Interleukin-2 receptor, alpha subunit (IL-2rα) levels, and higher Interferon gamma-induced protein 10 (IP-10) levels were associated with an increased risk of MPN (OR = 1.36,95%CI = 1.03–1.81, P = 0.032; OR = 1.55,95%CI = 1.09–2.22, P = 0.015; respectively).In addition, Genetically predicted MPN promotes expression of the inflammatory cytokines interleukin-10 (IL-10) (BETA = 0.033, 95% CI = 0.003 ~ 0.064, P = 0.032) and monokine induced by interferon-gamma (MIG) (BETA = 0.052, 95% CI = 0.002–0.102, P = 0.043) and, on activation, normal T cells express and secrete RANTES (BETA = 0.055, 95% CI = 0.0090.1, P = 0.018).

Conclusion

Our findings suggest that cytokines are essential to the pathophysiology of MPN. More research is required if these biomarkers can be used to prevent and treat MPN.
Appendix
Available only for authorised users
Literature
1.
2.
Tefferi A. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50–8.PubMedCrossRef
3.
Rungjirajittranon T, et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms. BMC Cancer. 2019;19(1):184.PubMedPubMedCentralCrossRef
4.
Abdul-Rahim AH, et al. National institutes of health stroke scale item profiles as predictor of patient outcome: external validation on independent trial data. Stroke. 2015;46(2):395–400.PubMedCrossRef
5.
Papageorgiou L, et al. Thrombotic and Hemorrhagic Issues Associated with Myeloproliferative Neoplasms. Clin Appl Thromb Hemost. 2022;28:10760296221097968.PubMedPubMedCentralCrossRef
6.
Brkic S, Meyer SC. Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. Hemasphere. 2021;5(1):e516.PubMedCrossRef
7.
8.
Verstovsek S, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.PubMedPubMedCentralCrossRef
9.
Cacemiro MDC, et al. Philadelphia-negative myeloproliferative neoplasms as disorders marked by cytokine modulation. Hematol Transfus Cell Ther. 2018;40(2):120–31.PubMedPubMedCentralCrossRef
10.
11.
12.
13.
Nachbaur DM, et al. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62(2–3):54–8.PubMedCrossRef
14.
Panteli KE, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol. 2005;130(5):709–15.PubMedCrossRef
15.
Ramanathan G, Fleischman AG. The Microenvironment in Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2021;35(2):205–16.PubMedCrossRef
16.
Hasselbalch HC. Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development? Leuk Res. 2013;37(2):214–20.PubMedCrossRef
17.
Smith GD, Ebrahim S. “Mendelian randomization”: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1–22.PubMedCrossRef
18.
19.
20.
Sun Y, et al. Assessing the causal role of hypertension on left atrial and left ventricular structure and function: A two-sample Mendelian randomization study. Front Cardiovasc Med. 2022;9:1006380.PubMedPubMedCentralCrossRef
21.
Ahola-Olli A, et al. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2017;100(1):40–50.PubMedCrossRef
22.
23.
24.
Larsson SC, et al. Type 2 diabetes, glucose, insulin, BMI, and ischemic stroke subtypes: Mendelian randomization study. Neurology. 2017;89(5):454–60.PubMedPubMedCentralCrossRef
25.
Bowden J, Hemani G, Davey Smith G. Invited Commentary: Detecting Individual and Global Horizontal Pleiotropy in Mendelian Randomization-A Job for the Humble Heterogeneity Statistic? Am J Epidemiol. 2018;187(12):2681–5.PubMedPubMedCentral
26.
Verbanck M, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.PubMedPubMedCentralCrossRef
27.
Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int J Epidemiol. 2011;40(3):740–52.PubMedCrossRef
28.
29.
Liu M, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011;22(3):121–30.PubMedPubMedCentral
30.
Karin N, Razon H. Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. Cytokine. 2018;109:24–8.PubMedCrossRef
31.
Obro NF, et al. Longitudinal Cytokine Profiling Identifies GRO-alpha and EGF as Potential Biomarkers of Disease Progression in Essential Thrombocythemia. Hemasphere. 2020;4(3):e371.PubMedPubMedCentralCrossRef
32.
Tefferi A, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.PubMedCrossRef
33.
Schnoder TM, et al. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. J Cancer Res Clin Oncol. 2017;143(5):807–20.PubMedCrossRef
34.
Allain-Maillet S, et al. Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1beta and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms. Cancers (Basel). 2020;12(9):2446.PubMedPubMedCentralCrossRef
35.
36.
Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science. 1986;232(4751):727–32.PubMedCrossRef
37.
Jones MC, et al. CD4 Effector TCR Avidity for Peptide on APC Determines the Level of Memory Generated. J Immunol. 2023;210(12):1950–61.PubMedCrossRef
38.
39.
Semenzato G, et al. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood. 1987;70(2):396–400.PubMedCrossRef
40.
Steis RG, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood. 1988;71(5):1304–9.PubMedCrossRef
41.
Wang JC, Wang A. Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis. Br J Haematol. 1994;86(2):380–2.PubMedCrossRef
42.
Bourantas KL, et al. Serum beta-2-microglobulin, TNF-alpha and interleukins in myeloproliferative disorders. Eur J Haematol. 1999;63(1):19–25.PubMedCrossRef
43.
Masselli E, et al. Protein kinase Cvarepsilon inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients. Leukemia. 2015;29(11):2192–201.PubMedCrossRef
44.
Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58–63.PubMedCrossRef
45.
Pourcelot E, et al. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.PubMedCrossRef
46.
Gangemi S, et al. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia. Cell Immunol. 2012;278(1–2):91–4.PubMedCrossRef
47.
Kleppe M, et al. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response. Cancer Discov. 2015;5(3):316–31.PubMedPubMedCentralCrossRef
48.
Li Q, et al. Activation of macrophage TBK1-HIF-1alpha-mediated IL-17/IL-10 signaling by hyperglycemia aggravates the complexity of coronary atherosclerosis: An in vivo and in vitro study. FASEB J. 2021;35(5):e21609.PubMedCrossRef
49.
Koenen RR, et al. Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009;15(1):97–103.PubMedCrossRef
50.
Shi H, et al. CRISPR/Cas9 based blockade of IL-10 signaling impairs lipid and tissue homeostasis to accelerate atherosclerosis. Front Immunol. 2022;13:999470.PubMedPubMedCentralCrossRef
51.
Park MK, et al. The CXC chemokine murine monokine induced by IFN-gamma (CXC chemokine ligand 9) is made by APCs, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo. J Immunol. 2002;169(3):1433–43.PubMedCrossRef
52.
Koper OM, et al. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration. Adv Clin Exp Med. 2018;27(6):849–56.PubMedCrossRef
53.
von Hundelshausen P, et al. RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation. 2001;103(13):1772–7.CrossRef
54.
Huo Y, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9(1):61–7.PubMedCrossRef
55.
56.
Xu S, et al. The role of interleukin-10 family members in cardiovascular diseases. Int Immunopharmacol. 2021;94:107475.PubMedCrossRef
57.
Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21(12):1876–90.PubMedCrossRef
58.
Han X, Boisvert WA. Interleukin-10 protects against atherosclerosis by modulating multiple atherogenic macrophage function. Thromb Haemost. 2015;113(3):505–12.PubMedCrossRef
59.
60.
Zhao Y, et al. Associations between type 2 diabetes mellitus and chronic liver diseases: evidence from a Mendelian ranldomization study in Europeans and East Asians. Front Endocrinol (Lausanne). 2024;15:1338465.PubMedCrossRef
61.
Au Yeung SL, et al. Evaluating the role of non-alcoholic fatty liver disease in cardiovascular diseases and type 2 diabetes: a Mendelian randomization study in Europeans and East Asians. Int J Epidemiol. 2023;52(3):921–31.PubMedCrossRef
62.
Ford I, et al. The inverse relationship between alanine aminotransferase in the normal range and adverse cardiovascular and non-cardiovascular outcomes. Int J Epidemiol. 2011;40(6):1530–8.PubMedCrossRef
Metadata
Title
Associations of the circulating levels of cytokines with the risk of myeloproliferative neoplasms: a bidirectional mendelian-randomization study
Authors
Hao Xiong
Huitao Zhang
Jun Bai
Yanhong Li
Lijuan Li
Liansheng Zhang
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Cytokines
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12301-x

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Deep learning-assisted diagnosis of benign and malignant parotid tumors based on ultrasound: a retrospective study

Research

Exploration of lymph node recurrence patterns and delineation guidelines of radiation field in middle thoracic oesophageal carcinomas after radical surgery: a real-world study

Research

OLFM2 promotes epithelial-mesenchymal transition, migration, and invasion in colorectal cancer through the TGF-β/Smad signaling pathway

Research

Evaluation of the diagnostic performance of colposcopy in the detection of cervical high-grade squamous intraepithelial lesions among women with transformation zone type 3

Research

Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR

Research

Apolipoprotein A-IV concentrations and cancer in a large cohort of chronic kidney disease patients: results from the GCKD study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits